Coronary
Editorial Comment
Drug-Eluting Stent Choice in Patients With Acute Myocardial Infarction

https://doi.org/10.1016/j.jcin.2019.09.008Get rights and content
Under an Elsevier user license
open archive

Key Words

drug-eluting stent
myocardial infarction
percutaneous coronary intervention

Cited by (0)

Dr. Windecker has received research and educational grants to the institution from Abbott, Amgen, Bayer, Bristol-Myers Squibb, Boston Scientific, Biotronik, CSL Behring, Edwards Lifesciences, Medtronic, Polares, and Sinomed. Dr. Pilgrim has received research grants to the institution from Biotronik, Symetis/Boston Scientific, and Edwards Lifesciences; has received speaking fees from Biotronik and Boston Scientific; and is a consultant for HighLife SAS. Dr. Ueki has reported that he has no relationships relevant to the contents of this paper to disclose.

Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology.